Novartis Ag (NVS) Free Cash Flow (2009 - 2026)

Novartis Ag has disclosed Free Cash Flow across 18 years of filings, most recently posting $6.2 billion for Q2 2026.

• In Q2 2026, Free Cash Flow fell 11.32% year-over-year to $6.2 billion; the TTM figure through Jun 2026 stood at $28.1 billion (up 11.39% YoY), while the FY2025 annual figure was $20.7 billion, up 8.99% from the prior year.
• Free Cash Flow came in at $6.2 billion for Q2 2026 at Novartis Ag, up from $4.0 billion in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $12.1 billion in Q4 2023 to a low of $1.9 billion in Q1 2022.
• Average Free Cash Flow over 5 years is $5.9 billion, with a median of $5.4 billion recorded in 2023.
• Year-over-year, Free Cash Flow surged 120.47% in 2022 and plunged 36.27% in 2024.
• Over 5 years, Free Cash Flow stood at $9.6 billion in 2022, then increased by 26.13% to $12.1 billion in 2023, then sank by 36.27% to $7.7 billion in 2024, then surged by 41.83% to $10.9 billion in 2025, then plunged by 43.19% to $6.2 billion in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $6.2 billion in Q2 2026, $4.0 billion in Q1 2026, and $10.9 billion in Q4 2025.